Novartis AG’s remibrutinib hits the Phase 3 MS endpoint, beating Aubagio amid BTK rival setbacks. Click for this NVS stock update.
Novartis: Today’s Positive Remibrutinib Data Key To Unlocking Growth Plans
view original post
Novartis AG’s remibrutinib hits the Phase 3 MS endpoint, beating Aubagio amid BTK rival setbacks. Click for this NVS stock update.